BD Names COO Thomas Polen As Next CEO; Vince Forlenza Will Retire In January
Executive Summary
Polen led BD’s $24bn acquisition of Bard in 2017 and the $12bn acquisition of CareFusion in 2015. Forlenza has been with BD for almost 40 years, including eight as CEO.
You may also be interested in...
BD Expects Alaris Infusion Pump To Return To US Market Next Year
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
Earnings Winners & Losers: Medtech 'Pure-Plays' BSX, ISRG, BDX, VAR, RMD
The third of three Winners and Losers features covering the companies that announced sales and earnings results in late July and early August looks at major companies that only market medical devices aside from the orthopedics device makers that were covered in an earlier Winners and Losers feature.
BD, CR Bard Merger To Create Vascular Access Device Giant
Becton Dickinson has reached a definitive agreement to acquire CR Bard for $24bn. BD says Bard's product portfolio gives it a strong presence in fast-growing clinical areas and more reach outside the US while Bard expects to reach more customers by building on BD's leadership in medication management and infection prevention.